Stifel raised the firm’s price target on Elanco (ELAN) to $27 from $23 and keeps a Buy rating on the shares. Elanco’s stock currently trades at a premium to Zoetis (ZTS), but it is now expected to grow faster in 2025 relative to the market leader, the analyst tells investors. “More importantly,” Elanco’s margins are half of Zoetis’ and the margin expansion opportunity is “significant” over the next 12-24 months, which should allow for EBITDA growth to outstrip Zoetis, the analyst added in a post-Q3 note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Elanco Animal Health: Strong U.S. Performance and Innovative Portfolio Drive Buy Rating
- Elanco raises FY25 adjusted EPS view to 91c-94c, consensus 91c
- Elanco sees Q4 adjusted EPS 9c-12c, consensus 14c
- Elanco reports Q3 EPS 19c, consensus 13c
- Elanco Animal Health Amends Credit Agreement for Refinancing
